Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling

Details for Australian Patent Application No. 2006247067 (hide)

Owner Novartis AG XOMA Technology Ltd.

Inventors Aukerman, Sharon Lea; Luqman, Mohammad; Jallal, Bahija

Agent FB Rice

Pub. Number AU-B-2006247067

PCT Pub. Number WO2006/125143

Priority 60/682,582 18.05.05 US; 60/749,285 09.12.05 US

Filing date 18 May 2006

Wipo publication date 23 November 2006

Acceptance publication date 7 June 2012

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

13 December 2007 PCT application entered the National Phase

  PCT publication WO2006/125143 Priority application(s): WO2006/125143

23 October 2008 Alteration of Name

  The name of the applicant has been altered to Novartis AG; XOMA Technology Ltd.

7 June 2012 Application Accepted

  Published as AU-B-2006247067

4 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006247072-Ambient curable protective sealant

2006247065-A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives